Rationale and delineation of a composite index of relative antitumoural efficacy (In-RATE).

[1]  O. S. Nielsen,et al.  Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group. , 2002, European journal of cancer.

[2]  J. Blay,et al.  Decision making process in oncology practice: is the information available and what should it consist of? , 2005, Critical reviews in oncology/hematology.

[3]  Steven Sun,et al.  Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. , 2004, Gynecologic oncology.

[4]  S. Cannistra.  The ethics of early stopping rules: who is protecting whom? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Benjamin,et al.  A two‐arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas , 2003, Cancer.

[6]  J. Expósito,et al.  New Chemotherapy Treatments in Advanced Cancer Patients An Easily Applicable Evaluation of Clinical Efficacy and Cost–effectiveness , 2003, Acta oncologica.

[7]  P. Thall,et al.  New designs for phase 2 clinical trials. , 2003, Blood.

[8]  S. Chan.  Second-line chemotherapy for ovarian cancer. , 2003, The Lancet. Oncology.

[9]  Douglas G. Altman,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials , 2001, The Lancet.

[10]  C. Runowicz,et al.  Current Therapies in Ovarian Cancer , 2003, Cancer investigation.

[11]  D. Armstrong.  Relapsed ovarian cancer: challenges and management strategies for a chronic disease. , 2002, The oncologist.

[12]  E. Eisenhauer,et al.  Novel endpoints and design of early clinical trials. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  P. Therasse,et al.  Evaluation of response: new and standard criteria. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  J. Sloan,et al.  The need for and characteristics of randomized, phase III trials to evaluate symptom management in patients with cancer. , 2002, Journal of the National Cancer Institute.

[15]  David Miles,et al.  Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M Van Glabbeke,et al.  Non-randomised phase II trials of drug combinations: often meaningless, sometimes misleading. Are there alternative strategies? , 2002, European journal of cancer.

[17]  O. S. Nielsen,et al.  Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. , 2002, European journal of cancer.

[18]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[19]  D Guthrie,et al.  Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Moher,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. , 2001, Journal of the American Podiatric Medical Association.

[21]  D. Moher,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials , 2001, The Lancet.

[22]  M. Gore,et al.  Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  I. Smith,et al.  New treatments for advanced cancer: an approach to prioritization , 2000, British Journal of Cancer.

[24]  P. Hemyari.  ROBUSTNESS OF THE QUARTILES OF SURVIVAL TIME AND SURVIVAL PROBABILITY , 2000, Journal of biopharmaceutical statistics.

[25]  J. Dancey,et al.  Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. James,et al.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.

[27]  M. van Glabbeke,et al.  Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[29]  A. Cesano,et al.  Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients. , 1999, International journal of oncology.

[30]  Christian Jacques,et al.  Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer , 1998, The Lancet.

[31]  A Gordon,et al.  Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  I. Olkin,et al.  Improving the quality of reporting of randomized controlled trials. The CONSORT statement. , 1996, JAMA.

[33]  E. Partridge,et al.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, The New England journal of medicine.

[34]  Kenneth F. Schulz,et al.  The CONSORT Statement , 1996 .